ASTRO/SNO Joint Activity: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?
The management of patients with grade 2 – 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy.
Category
  • Central Nervous System
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Designing, Implementing and Interpreting Patient Reported Outcomes in Clinical Investigation
Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.
Category
  • Professional Development
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $0.00
Empowering Survivorship: Addressing Pelvic Health Challenges in GI and GYN Cancer Patients Post-Radiation Therapy
Despite the increasing recognition of the long-term effects of radiation therapy on pelvic health, many healthcare providers remain inadequately trained to address these specific issues.
Category
  • Gastrointestinal
  • Gynecologic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00

Pages